Related Experiment Videos
Caspase inhibitors: a pharmaceutical industry perspective.
1Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, CA 92121, USA. slinton@idun.com
Current Topics in Medicinal Chemistry
|December 27, 2005
Summary
Caspase inhibition effectively moderates excessive programmed cell death (apoptosis). Pharmaceutical research is advancing caspase inhibitors, including VX-740 and IDN-6556, into clinical trials for various diseases.
Area of Science:
- Biochemistry
- Pharmacology
- Cell Biology
Background:
- Excessive programmed cell death (apoptosis) contributes to various pathologies.
- Caspase inhibition is a therapeutic strategy to modulate apoptosis.
- Recent pharmaceutical research highlights the growing interest in caspase inhibitors.
Purpose of the Study:
- To summarize recent advancements in caspase inhibition research.
- To outline the therapeutic potential of targeting caspases across multiple disease indications.
- To review compounds progressing into clinical trials.
Main Methods:
- Review of scientific literature and publications.
- Analysis of Structure-Activity Relationship (SAR) studies.
- Evaluation of preclinical animal models of disease.
Main Results:
- Caspase inhibition demonstrates therapeutic efficacy in moderating apoptosis.
- Broad applicability of caspase inhibition across diverse disease areas.
- Advancement of specific caspase inhibitors into clinical trials.
Conclusions:
- Caspase inhibition is a validated therapeutic approach for diseases involving excessive apoptosis.
- Compounds like VX-740, VX-765, and IDN-6556 represent promising clinical candidates.
- The field of caspase inhibition has matured, with significant therapeutic potential.